TN2014000337A1 - Cancer patient selection for administration of wnt signaling inhibitors using rnf43 mutation status - Google Patents
Cancer patient selection for administration of wnt signaling inhibitors using rnf43 mutation statusInfo
- Publication number
- TN2014000337A1 TN2014000337A1 TNP2014000337A TN2014000337A TN2014000337A1 TN 2014000337 A1 TN2014000337 A1 TN 2014000337A1 TN P2014000337 A TNP2014000337 A TN P2014000337A TN 2014000337 A TN2014000337 A TN 2014000337A TN 2014000337 A1 TN2014000337 A1 TN 2014000337A1
- Authority
- TN
- Tunisia
- Prior art keywords
- rnf43
- znrf3
- administration
- cancer patient
- wnt signaling
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Hospice & Palliative Care (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261604290P | 2012-02-28 | 2012-02-28 | |
PCT/US2013/027441 WO2013130364A1 (fr) | 2012-02-28 | 2013-02-22 | Sélection de patient atteints d'un cancer pour administrer des inhibiteurs de signalisation de la voie wnt au moyen de l'état de mutation rnf43 |
Publications (1)
Publication Number | Publication Date |
---|---|
TN2014000337A1 true TN2014000337A1 (en) | 2015-12-21 |
Family
ID=47790546
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TNP2014000337A TN2014000337A1 (en) | 2012-02-28 | 2014-08-05 | Cancer patient selection for administration of wnt signaling inhibitors using rnf43 mutation status |
Country Status (20)
Country | Link |
---|---|
US (3) | US20150125857A1 (fr) |
EP (2) | EP2820151B1 (fr) |
JP (2) | JP6397335B2 (fr) |
KR (1) | KR20140132712A (fr) |
CN (1) | CN104302782A (fr) |
AU (1) | AU2013226323B2 (fr) |
BR (1) | BR112014020233A2 (fr) |
CA (1) | CA2864306A1 (fr) |
CL (1) | CL2014002269A1 (fr) |
ES (2) | ES2797533T3 (fr) |
HK (1) | HK1199744A1 (fr) |
IL (1) | IL233920A0 (fr) |
MX (1) | MX2014010265A (fr) |
NZ (1) | NZ627864A (fr) |
PH (1) | PH12014501930A1 (fr) |
RU (2) | RU2636000C2 (fr) |
SG (1) | SG11201404492VA (fr) |
TN (1) | TN2014000337A1 (fr) |
WO (1) | WO2013130364A1 (fr) |
ZA (1) | ZA201405553B (fr) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3281640A1 (fr) | 2011-06-17 | 2018-02-14 | President and Fellows of Harvard College | Frizzled 2 en tant que cible pour des anticorps thérapeutiques dans le traitement du cancer |
EP2766033B1 (fr) | 2011-10-14 | 2019-11-20 | Novartis AG | Anticorps et méthodes pour traiter des maladies associées à la voie de signalisation wnt |
BR112014020233A2 (pt) | 2012-02-28 | 2017-07-04 | Irm Llc | seleção de paciente com câncer para administração de inibidores sinalizantes wnt usando status de mutação rnf43 |
US9713612B2 (en) | 2013-03-12 | 2017-07-25 | Curegenix, Inc. | Compounds for treatment of cancer |
WO2015145388A2 (fr) * | 2014-03-27 | 2015-10-01 | Novartis Ag | Procédés de traitement de cancers colorectaux avec mutations en amont de la voie wnt |
JP2017518040A (ja) * | 2014-04-21 | 2017-07-06 | アッヴィ・ステムセントルクス・エル・エル・シー | 新規の抗rnf43抗体および使用方法 |
HUE046914T2 (hu) * | 2014-10-08 | 2020-04-28 | Redx Pharma Plc | N-piridinil-acetamid-származékok, mint a WNT jelátviteli út inhibitorai |
US20160312207A1 (en) * | 2015-04-21 | 2016-10-27 | The Board Of Trustees Of The Leland Stanford Junior University | R-spondin antagonists and methods of treating cancer associated with aberrant activation of wnt signaling |
EP3302479A4 (fr) * | 2015-05-26 | 2019-01-09 | Curegenix Corporation | Biomarqueurs tumoraux et leur utilisation |
US11993645B2 (en) | 2017-01-11 | 2024-05-28 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions comprising R-Spondin (RSPO) surrogate molecules |
JP7305543B2 (ja) * | 2017-01-26 | 2023-07-10 | スロゼン オペレーティング, インコーポレイテッド | 組織特異的Wntシグナル増強分子およびその使用 |
WO2019245460A1 (fr) * | 2018-06-21 | 2019-12-26 | National University Of Singapore | Stratification de patients cancéreux hébergeant des mutations oncogènes dans l'ubiquitine ligase e3 rnf43 |
US20210299233A1 (en) * | 2018-07-12 | 2021-09-30 | The Children's Medical Center Corporation | Method for treating cancer |
CA3141632A1 (fr) | 2019-06-21 | 2020-12-24 | Regeneron Pharmaceuticals, Inc. | Traitement de densite minerale osseuse reduite avec des inhibiteurs de zinc et doigt ring 3 (znrf3) |
CN113564249B (zh) * | 2020-04-28 | 2023-06-16 | 中国科学院分子细胞科学卓越创新中心 | CXorf67在判断肿瘤对DNA损伤药物的敏感性中的应用 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101008758B1 (ko) | 2001-09-18 | 2011-01-14 | 제넨테크, 인크. | 종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물 |
EP1513934B1 (fr) | 2002-06-06 | 2011-03-02 | Oncotherapy Science, Inc. | Genes et polypeptides en rapport avec les cancers du colon chez l'homme |
ES2361541T3 (es) * | 2002-06-06 | 2011-06-17 | Oncotherapy Science, Inc. | Genes y polipéptidos relacionados con cánceres de colon humanos. |
WO2004032838A2 (fr) * | 2002-10-04 | 2004-04-22 | The Regents Of The University Of California | Methodes de traitement du cancer par inhibition de la signalisation de wnt |
WO2004086949A2 (fr) | 2003-03-25 | 2004-10-14 | John Wayne Cancer Institute | Marqueurs d'adn utilises dans la gestion du cancer |
CN101687005A (zh) * | 2004-07-09 | 2010-03-31 | 加利福尼亚大学董事会 | 采用抑制Wnt 16信号转导的试剂治疗癌症的方法 |
JP2008519829A (ja) * | 2004-11-10 | 2008-06-12 | ヒュブレヒト ラボラトリウム | Notch経路活性化の阻害による腸腺腫および/または腺癌の処置 |
JP5085529B2 (ja) | 2005-03-16 | 2012-11-28 | オーエスアイ・フアーマシユーテイカルズ・エル・エル・シー | 上皮成長因子受容体キナーゼ阻害剤に対する抗癌応答を予測する生物学的マーカー |
UA103918C2 (en) | 2009-03-02 | 2013-12-10 | Айерем Элелси | N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators |
WO2011004379A1 (fr) * | 2009-07-10 | 2011-01-13 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Compositions et méthodes de traitement du cancer |
EP2549399A1 (fr) | 2011-07-19 | 2013-01-23 | Koninklijke Philips Electronics N.V. | Evaluation d'activité de voie Wnt utilisant un modelage probabilistique d'expression de gène cible |
EP2766033B1 (fr) | 2011-10-14 | 2019-11-20 | Novartis AG | Anticorps et méthodes pour traiter des maladies associées à la voie de signalisation wnt |
BR112014020233A2 (pt) | 2012-02-28 | 2017-07-04 | Irm Llc | seleção de paciente com câncer para administração de inibidores sinalizantes wnt usando status de mutação rnf43 |
WO2017093478A1 (fr) | 2015-12-04 | 2017-06-08 | Boehringer Ingelheim International Gmbh | Polypeptides biparatopiques ayant un effet antagoniste sur la signalisation wnt dans des cellules tumorales |
-
2013
- 2013-02-22 BR BR112014020233A patent/BR112014020233A2/pt active Search and Examination
- 2013-02-22 WO PCT/US2013/027441 patent/WO2013130364A1/fr active Application Filing
- 2013-02-22 ES ES13707527T patent/ES2797533T3/es active Active
- 2013-02-22 EP EP13707527.1A patent/EP2820151B1/fr active Active
- 2013-02-22 CA CA2864306A patent/CA2864306A1/fr not_active Abandoned
- 2013-02-22 CN CN201380011506.6A patent/CN104302782A/zh active Pending
- 2013-02-22 RU RU2014139044A patent/RU2636000C2/ru active
- 2013-02-22 US US14/380,776 patent/US20150125857A1/en not_active Abandoned
- 2013-02-22 JP JP2014559931A patent/JP6397335B2/ja active Active
- 2013-02-22 MX MX2014010265A patent/MX2014010265A/es unknown
- 2013-02-22 RU RU2017120287A patent/RU2017120287A/ru not_active Application Discontinuation
- 2013-02-22 NZ NZ627864A patent/NZ627864A/en not_active IP Right Cessation
- 2013-02-22 ES ES20154250T patent/ES2968742T3/es active Active
- 2013-02-22 SG SG11201404492VA patent/SG11201404492VA/en unknown
- 2013-02-22 KR KR1020147023667A patent/KR20140132712A/ko active IP Right Grant
- 2013-02-22 EP EP20154250.3A patent/EP3693476B1/fr active Active
- 2013-02-22 AU AU2013226323A patent/AU2013226323B2/en active Active
-
2014
- 2014-07-28 ZA ZA2014/05553A patent/ZA201405553B/en unknown
- 2014-07-31 IL IL233920A patent/IL233920A0/en unknown
- 2014-08-05 TN TNP2014000337A patent/TN2014000337A1/fr unknown
- 2014-08-27 PH PH12014501930A patent/PH12014501930A1/en unknown
- 2014-08-27 CL CL2014002269A patent/CL2014002269A1/es unknown
-
2015
- 2015-01-08 HK HK15100179.6A patent/HK1199744A1/xx unknown
-
2016
- 2016-12-20 US US15/385,088 patent/US20170306409A1/en not_active Abandoned
-
2018
- 2018-06-26 JP JP2018120856A patent/JP2018172408A/ja active Pending
-
2019
- 2019-01-28 US US16/259,419 patent/US20190203301A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
ES2797533T3 (es) | 2020-12-02 |
ES2968742T3 (es) | 2024-05-13 |
MX2014010265A (es) | 2015-06-23 |
EP2820151B1 (fr) | 2020-03-25 |
US20150125857A1 (en) | 2015-05-07 |
AU2013226323B2 (en) | 2016-07-14 |
IL233920A0 (en) | 2014-09-30 |
CA2864306A1 (fr) | 2013-09-06 |
JP6397335B2 (ja) | 2018-09-26 |
PH12014501930A1 (en) | 2014-11-24 |
NZ627864A (en) | 2015-12-24 |
JP2018172408A (ja) | 2018-11-08 |
SG11201404492VA (en) | 2014-10-30 |
EP3693476B1 (fr) | 2023-10-18 |
HK1199744A1 (en) | 2015-07-17 |
CL2014002269A1 (es) | 2014-12-19 |
CN104302782A (zh) | 2015-01-21 |
AU2013226323A1 (en) | 2014-09-11 |
BR112014020233A2 (pt) | 2017-07-04 |
EP3693476A1 (fr) | 2020-08-12 |
EP2820151A1 (fr) | 2015-01-07 |
RU2014139044A (ru) | 2016-04-20 |
US20170306409A1 (en) | 2017-10-26 |
WO2013130364A1 (fr) | 2013-09-06 |
RU2636000C2 (ru) | 2017-11-17 |
RU2017120287A (ru) | 2018-11-15 |
KR20140132712A (ko) | 2014-11-18 |
JP2015511484A (ja) | 2015-04-20 |
US20190203301A1 (en) | 2019-07-04 |
ZA201405553B (en) | 2015-12-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12014501930A1 (en) | Cancer patient selection for administration of wnt signaling inhibitors using rnf43 mutation status | |
AU2018256477A1 (en) | Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or AHI1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof | |
MX2022000085A (es) | Metodos de terapia genica para enfermedades y condiciones relacionadas con la edad. | |
MX2023002251A (es) | Antagonistas de union al eje pd-l1 y usos de los mismos para el tratamiento de cancer. | |
EA201500334A1 (ru) | Fgfr3 гибридный ген и лекарственный препарат, нацеленный на него | |
NZ736853A (en) | Methods of treating cancer patients with farnesyl transferase inhibitors | |
IL238015A0 (en) | Methods to prevent cancer metastases, treatment and prognosis of cancer and identification of potential metastasis inhibitors | |
TN2014000063A1 (en) | Kinase inhibitor polymorphs | |
BR112014023162A8 (pt) | compostos e métodos para modulação quinase e indicações dos mesmos | |
TN2013000412A1 (en) | Bcma-based stratification and therapy for multiple myeloma patients | |
WO2014200952A3 (fr) | Marqueurs génétiques de la réponse aux antipsychotiques | |
EP3284481A4 (fr) | Agent induisant la mort cellulaire pour des cellules ayant une mutation du gène braf, agent pour inhiber la prolifération desdites cellules et composition pharmaceutique pour le traitement d'un patient souffrant des effets de la prolifération anormale desdites cellules | |
MX2017002364A (es) | Terapia de combinacion para tratamiento de cancer. | |
IN2014MN01945A (fr) | ||
MX2014014097A (es) | Biomarcadores para determinar la respuesta eficaz de tratamientos en pacientes de carcinoma hepatocelular (chc). | |
MX2021000133A (es) | Uso de compuestos conocidos como inhibidores de la d-aminoacido oxidasa. | |
HRP20180130T1 (hr) | Protutumorsko sredstvo i postupak predviđanja terapijskog učinka za pacijente s kolorektalnim rakom s mutacijom kras | |
GB2523211A8 (en) | MCT protein inhibitor-related prognostic and therapeutic methods | |
WO2012109233A3 (fr) | Procédés de prédiction du risque de récidive chez des patients atteints d'un cancer du sein | |
EA201491780A1 (ru) | Мутанты c-raf, придающие резистентность к ингибиторам raf | |
MX2016004212A (es) | Inhibidor de tor cinasa en la prevencion o tratamiento de cancer caracterizado por mutaciones genicas. | |
WO2013103836A3 (fr) | Procédés de traitement du cancer | |
UA96043U (uk) | Спосіб прогнозування зрощення перелому | |
UA96597U (uk) | Спосіб прогнозування зрощення перелому | |
UA96593U (uk) | Спосіб прогнозування зрощення перелому |